title: Celecoxib, rofecoxib, and acute temporary visual impairment.
authors: Intensive Medicines Monitoring Programme, New Zealand Pharmacovigilance Centre, Department of Preventive and Social Medicine, Dunedin School of Medicine, University of Otago, PO Box 913, Dunedin 9000, New Zealand. david.coulter@stonebow.otago.ac.nz
authors: David Morris
authors: DM
authors: Coulter
authors: David Walter John
authors: DW
authors: Clark
authors: Ruth Lesley
authors: RL
authors: Savage
mesh_terms: D000208:Acute Disease; D000368:Aged; D000369:Aged, 80 and over; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D000068579:Celecoxib; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007783:Lactones / Q000009:adverse effects*; D008297:Male; D010149:Postoperative Pain / Q000517:prevention & control; D011720:Pyrazoles; D013449:Sulfonamides / Q000009:adverse effects*; D013450:Sulfones; D014786:Vision Disorders / Q000139:chemically induced*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D011720:Pyrazoles; D013449:Sulfonamides; D013450:Sulfones; C116926:rofecoxib; D000068579:Celecoxib